First human tests begin for experimental obesity medication
NCT ID NCT07170319
Summary
This early-stage study is testing the safety and side effects of a new weight management drug called IBI3032 in people who are overweight or have obesity. The trial involves 79 participants who will receive either the drug or a placebo over 4 weeks. Researchers are primarily checking how well people tolerate the medication and how their bodies process it, rather than measuring weight loss effectiveness at this stage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
Conditions
Explore the condition pages connected to this study.